IP Library Granted Patent US 12,016,972
Granted Patent B2
US 12,016,972 · App. 18/157,653 · Granted Jun 25, 2024

Surgical repair graft

Inventor: E. Skott Greenhalgh (Gladwyne, PA)
Assignee: TELA Bio, Inc.
A61L27/52A61L27/24A61L27/54A61L27/58A61L2300/626A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,016,972
App. No.
18/157,653
Granted
Jun 25, 2024
Kind
B2
Abstract

The apparatuses and methods described herein relates generally to the field of active agent (drug) release from surgical grafts useful for soft tissue reconstruction, regeneration, or repair. More particularly, described herein are surgical grafts for soft tissue repair that include an active agent that is released over time while advantageously matching the biomechanical properties of tissue during healing and recovery.

Claims (27)

1. A method for controlled release of an active agent from a surgical repair graft comprising:

exposing the surgical repair graft having one biotextile layer or a plurality of stacked biotextile layers and a bioabsorbable carrier matrix attached to at least one of the one or plurality of stacked biotextile layers to an aqueous fluid, the carrier matrix comprising the active agent, wherein the bioabsorbable carrier matrix comprises particles each having non-concentric internally aqueous chambers, wherein the particles are attached to the bioabsorbable carrier matrix at discrete attachments sites as islands that are spaced apart from each other to provide axial compliance to the surgical repair graft during bending; and

degrading the carrier matrix over time by the aqueous fluid to thereby release the active agent from the carrier matrix.

2. The method of claim 1 , wherein the non-concentric internally aqueous chambers are surrounded by lipid membranes, one or more of the internally aqueous chambers and the lipid membranes containing the active agent, wherein a first set of the chambers are on the exterior of the particles and a second set of chambers are on the interior of the particles, wherein lipid membranes on the first set of chambers are degraded first and lipid membranes on the second set of chambers are degraded later during the degrading step.

3. The method of claim 1 , wherein at least one of the one biotextile layer or plurality of biotextile layers comprises pores, the method further comprising flowing active agent from the carrier matrix through the pores to thereby release active agent to a body region adjacent the biotextile layer.

4. The method of claim 1 , wherein a hydrogel is adhered to at least one of the layers, the method further comprising degrading the hydrogel.

5. The method of claim 1 , wherein a compliance strain of the surgical repair graft is between 10-30% at 16 N/cm prior to the degrading step.

6. The method of claim 1 , wherein the active agent comprises an active pharmaceutical ingredient (API).

7. A method for controlled release of an active agent from a surgical repair graft comprising:

exposing the surgical repair graft having one biotextile layer or a plurality of stacked biotextile layers and a bioabsorbable carrier matrix attached to at least one of the one or plurality of stacked biotextile layers to an aqueous fluid, the carrier matrix comprising the active agent; and

degrading the carrier matrix over time by the aqueous fluid to thereby release the active agent from the carrier matrix,

wherein the bioabsorbable carrier matrix comprises particles including multivesicular liposomes having non-concentric internally aqueous chambers, wherein the particles are attached to the bioabsorbable carrier matrix at discrete attachments sites as islands that are spaced apart from each other to provide axial compliance to the surgical repair graft during bending.

8. The method of claim 7 , wherein the non-concentric internally aqueous chambers are surrounded by lipid membranes, one or more of the internally aqueous chambers and the lipid membranes containing the active agent, wherein a first set of the chambers are on the exterior of the particles and a second set of chambers are on the interior of the particles, wherein lipid membranes on the first set of chambers are degraded first and lipid membranes on the second set of chambers are degraded later during the degrading step.

9. The method of claim 7 , wherein at least one of the one biotextile layer or plurality of biotextile layers comprises pores, the method further comprising flowing active agent from the carrier matrix through the pores to thereby release active agent to a body region adjacent the biotextile layer.

10. The method of claim 7 , wherein a hydrogel is adhered to at least one of the layers, the method further comprising degrading the hydrogel.

11. The method of claim 7 , wherein a compliance strain of the surgical repair graft is between 10-30% at 16 N/cm prior to the degrading step.

12. The method of claim 7 , wherein the active agent comprises an active pharmaceutical ingredient (API).

13. A method for controlled release of an active agent from a surgical repair graft comprising:

exposing the surgical repair graft having one biotextile layer or a plurality of stacked biotextile layers and a bioabsorbable carrier matrix attached to at least one of the one or plurality of stacked biotextile layers to an aqueous fluid, the carrier matrix comprising the active agent; and

degrading the carrier matrix over time by the aqueous fluid to thereby release the active agent from the carrier matrix,

wherein the bioabsorbable carrier matrix comprises a plurality of particles each having a plurality non-concentric internally aqueous chambers surrounded by lipid membranes, one or more of the internally aqueous chambers and the lipid membranes containing the active agent, wherein the particles are attached to the bioabsorbable carrier matrix at discrete attachments sites as islands that are spaced apart from each other to provide axial compliance to the surgical repair graft during bending.

14. The method of claim 13 , wherein one or more of the internally aqueous chambers and the lipid membranes contain the active agent, wherein a first set of the chambers are on the exterior of the particles and a second set of chambers are on the interior of the particles, wherein lipid membranes on the first set of chambers are degraded first and lipid membranes on the second set of chambers are degraded later during the degrading step.

15. The method of claim 13 , wherein at least one of the one biotextile layer or plurality of biotextile layers comprises pores, the method further comprising flowing active agent from the carrier matrix through the pores to thereby release active agent to a body region adjacent the biotextile layer.

16. The method of claim 13 , wherein a hydrogel is adhered to at least one of the layers, the method further comprising degrading the hydrogel.

17. The method of claim 13 , wherein a compliance strain of the surgical repair graft is between 10-30% at 16 N/cm prior to the degrading step.

18. The method of claim 13 , wherein the active agent comprises an active pharmaceutical ingredient (API).

19. The method of claim 1 , wherein the discrete attachment sites are arranged in a pattern having a density that is less than about 10 attachments per millimeter squared (mm 2 ).

Assignments (3)
SECURITY INTEREST Recorded Nov 14, 2025
From: TELA BIO, INC.
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 072905/0537 →
AFTER-ACQUIRED IP SECURITY AGREEMENT (FOURTH SUPPLEMENTAL FILING) Recorded Apr 18, 2023
From: PREMIER NUTRITION COMPANY, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 063362/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2023
From: GREENHALGH, E. SKOTT
To: TELA BIO, INC.
Reel/Frame 062443/0542 →